Leukapheresis Clinical Trials
36 recruitingProcedure
Phase 122Phase 210Early Phase 14Phase 32
Showing 1–20 of 36 trials
Recruiting
Phase 3
Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma
NeuroblastomaGanglioneuroblastoma, Nodular
National Cancer Institute (NCI)478 enrolled178 locationsNCT06172296
Recruiting
Phase 1
Study of CD19 Allogeneic Memory T-cell Therapy for Relapsed/Refractory CD19+ Leukemia
Pediatric ALLAcute Lymphoblastic Leukemia, in RelapseAcute Lymphoblastic Leukemia Refractory
St. Jude Children's Research Hospital60 enrolled1 locationNCT04881240
Recruiting
Phase 1
CARPALL: Immunotherapy With CD19+CD22 CAR T-cells for CD19+ and CD22+ Acute Lymphoblastic Leukaemia
Acute Lymphoblastic Leukemia
University College, London50 enrolled3 locationsNCT02443831
Recruiting
Phase 1
A2-ESO-1 TCR-Engineered T Cells for Relapsed/Refractory Advanced or Metastatic NY-ESO-1 Overexpression Positive Triple Negative Breast Cancer
Triple-Negative Breast Cancer
University of Southern California20 enrolled1 locationNCT05989828
Recruiting
Phase 1
A Phase 1 Study of JV-213 Autologous CD79b-targeting Chimeric Antigen Receptor T-cell Therapy in Adults With Relapsed or Refractory B-cell Lymphomas
LymphomasB-cell Lymphomas
M.D. Anderson Cancer Center33 enrolled1 locationNCT05773040
Recruiting
Phase 3
Testing Whether High Dose Chemotherapy and Infusion of the Patients' Own Stem Cells Improves Survival in Patients With Peripheral T-cell Lymphoma Who Achieved a Complete Response at the End of the Initial Chemotherapy
Peripheral T-Cell Lymphoma, Not Otherwise SpecifiedAnaplastic Large Cell Lymphoma, ALK-negativeFollicular Helper T-Cell Lymphoma+1 more
Eastern Cooperative Oncology Group294 enrolled158 locationsNCT06724237
Recruiting
Phase 1
Locoregional Administration of Genetically Engineered Cells (EGFR/IL13Rα2 Pool-CAR T Cells) for the Treatment of Recurrent or Progressive High-Grade Gliomas
Recurrent Astrocytoma, IDH-Mutant, Grade 4Recurrent Glioblastoma, IDH-Wildtype
City of Hope Medical Center24 enrolled1 locationNCT07544992
Recruiting
Phase 2
Odronextamab for Relapsed and Refractory Large B-cell Lymphomas Before CAR-T
Recurrent Diffuse Large B-Cell LymphomaRefractory Diffuse Large B-Cell LymphomaRecurrent High Grade B-Cell Lymphoma+9 more
University of Washington27 enrolled1 locationNCT06784726
Recruiting
Early Phase 1
N-803 in Patients With Progressive Synovial Sarcoma and Myxoid/Round Cell Liposarcoma Previously Treated With Adoptive Cellular Therapy
Synovial SarcomaMyxoid LiposarcomaRound Cell Liposarcoma
Northwestern University8 enrolled1 locationNCT07261657
Recruiting
The Use of Leukapheresis to Support HIV Pathogenesis Studies
HIV
University of California, San Francisco100 enrolled1 locationNCT01161199
Recruiting
Phase 2
Phase 2 Trial of Lisocabtagene Maraleucel for Minimal Residual Disease in Patients With Large B-cell Lymphoma
Large B-cell Lymphoma
M.D. Anderson Cancer Center10 enrolled1 locationNCT07316010
Recruiting
Early Phase 1
Allogeneic CMV-Specific CD19-CAR T Cells Plus CMV-MVA Triplex Vaccine After Matched Related Donor Hematopoietic Cell Transplant for the Treatment of Patients With High-Risk Acute Lymphoblastic Leukemia
Acute Lymphoblastic Leukemia
City of Hope Medical Center15 enrolled1 locationNCT06735690
Recruiting
Phase 1
177^Lu-PSMA-617 in Combination With Sipuleucel-T for the Treatment of Metastatic Castration-Resistant Prostate Cancer
Stage IVB Prostate Cancer AJCC v8Metastatic Castration-Resistant Prostate Adenocarcinoma
City of Hope Medical Center30 enrolled1 locationNCT07219147
Recruiting
Phase 1
CS1-CAR T Therapy Following Chemotherapy in Treating Patients With Relapsed or Refractory CS1 Positive Multiple Myeloma
Recurrent Plasma Cell MyelomaRefractory Plasma Cell Myeloma
City of Hope Medical Center30 enrolled1 locationNCT03710421
Recruiting
Early Phase 1
Personalized Dendritic Cell Vaccine Pilot for High Risk TNBC After Neoadjuvant Therapy
Breast CancerTriple-Negative Breast Cancer
H. Lee Moffitt Cancer Center and Research Institute16 enrolled1 locationNCT06435351
Recruiting
Phase 1
Genetically Engineered Cells (CD83 CAR T Cells) for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia
Recurrent Acute Myeloid LeukemiaRefractory Acute Myeloid Leukemia
Roswell Park Cancer Institute26 enrolled1 locationNCT06871410
Recruiting
Phase 1
MUC1-Activated T Cells for the Treatment of Relapsed and Resistant Ovarian Cancer
Recurrent Ovarian CarcinomaRecurrent Fallopian Tube CarcinomaRecurrent Primary Peritoneal Carcinoma+13 more
Mayo Clinic12 enrolled1 locationNCT06483048
Recruiting
Phase 1
Anti-EGFRvIII synNotch Receptor Induced Anti-EphA2/IL-13Ralpha2 CAR (E-SYNC) T Cells
GlioblastomaEGFR Gene MutationMGMT-Unmethylated Glioblastoma+1 more
Hideho Okada, MD, PhD20 enrolled1 locationNCT06186401
Recruiting
Phase 1
CRISPR Delivered Anti-BCMA Car-T Therapy for Relapsed or Refractory Multiple Myeloma
Multiple MyelomaRefractory Multiple MyelomaRecurrent Multiple Myeloma
Thomas Martin, MD30 enrolled1 locationNCT07340853
Recruiting
Phase 2
Pembro Plus CAR T-cell Therapy in R/R in PMBCL
Primary Mediastinal Large B Cell LymphomaPrimary Mediastinal Large B-cell Lymphoma (PMBCL)Primary Mediastinal Large B-Cell Lymphoma Refractory+3 more
Jennifer Crombie, MD35 enrolled2 locationsNCT05934448